Introduction
The management of non-cardiac surgery after percutaneous coronary intervention (PCI) and coronary stent implantation is a frequent and important concern in perioperative care.
Percutaneous coronary interventions are common, with 1.2 million procedures performed every year in North America alone. 1, 2 Of patients who receive coronary stents, 5% subsequently undergo non-cardiac surgery within one year, 3, 4 corresponding to 60,000 patients annually in
North America. The perioperative period poses important risks for such individuals. Risks of stent thrombosis and adverse cardiac events are increased due to the pro-thrombotic state induced by the surgical stress response, 5 as well as the potential disruption of anti-platelet medications. Conversely, if anti-platelet medications are continued to mitigate the risk of stent thrombosis, patients may suffer increased risks of major hemorrhage, which itself associated with increased mortality. 6 Given these opposing risks, practice guidelines recommend that elective non-cardiac surgery be delayed until surgery can be performed safely using anti-platelet therapy with aspirin alone. The suggested delay is 30 to 45 days for bare-metal stents and one-year for drug-eluting stents. 7, 8 These recommendations have important implications especially since 70% of North
American patients who undergo PCI receive drug-eluting stents. 9 Specifically, many such individuals may not be able to defer their planned surgery for a year.
These recommendations are largely based on expert opinion, as well as reports that
showed an increased risk of adverse cardiac events when non-cardiac surgery was performed shortly after stent implantation. 4, [10] [11] [12] [13] However, these previous reports have important limitations.
Some were single-center studies with limited generalizability. [11] [12] [13] In addition, the association between non-cardiac surgery soon after PCI and adverse events may have been confounded by medications. Conversely, if anti-platelet medications are continued to mitigate th the e ri ri risk sk k o of f f st st sten en e t t hrombosis, patients may suffer increased risks of major hemorrhage, which itself associated wi with th h i i in nc ncre re eas as ased ed e m m mor or orta t lity. 6 Given th th hes es e e e op op ppo o osi si sing ng ng r r ris isks ks s, , , pr prac act tice gu u uide e eli in nes s s r re reco co om mm mme en end d th th ha a at e e ele lec ct cti iv ive e n n non n-n-ca card rd di ia iac c c u urg rg rger er ery y y be be d d del e elay ay yed ed d u un nt ntil l s su urge ge gery ry y c c can an an b be e e pe pe perf rf rfor r rme me m d d d s sa s f fe fely ly y u u us sing ng ng a a ant nt ti-i-i-pl pla a ate el elet et t t the he hera ra apy py py w wi i ith h h as asp p pir ri rin n alone. The sug ug ugge ge gest st sted ed ed d d del e e ay ay y i is s s 30 0 0 t t to o 45 4 4 d d day ay ays s s fo fo for r r ba ba are re r -m -met et etal al al s ste te t nt nt nts s s an n nd d d on on one-e-e ye ye year ar r f f for or or d d dru ru rug-eluting the inclusion of urgent-to-emergent surgeries in several studies. 4, 10, 12, 13 Specifically, urgent-toemergent procedures, which are likely to necessitate non-cardiac surgery soon after PCI, are associated with an almost four-fold increased risk of mortality. 6 Given the important implications of current guideline recommendations for the perioperative care of patients with coronary stents, and the limitations to the related literature, we conducted a population-based cohort study to evaluate the outcomes of patients who underwent elective intermediate-to-high risk non-cardiac surgery in Ontario, Canada following stent implantation.
Methods
The [16] [17] [18] [19] [20] Since the Cardiac Care Network registry is
The Cardiac Care Network of Ontario maintains a prospective clinical registry of all individuals wh who o o un un unde de derg rg rgo o ca ard rd rdi ia iac catheterization, PCI, or cor r ron on o a ary artery byp pas as a s gr gr raf af aft ting (CABG) surgery in O O Ont ta tario, Canad ada a. . 14 4 4,15 5 5 A A All ll l h h hos os ospi pi pita tals ls s p p per erfo for rmin n ng g g PC CI a are e re re equ qu uir red ed t t to co oll ll lle ec ect t in in nfo fo form rmat at atio io on n on on on pa pati ti tien en nts ts t ' cl cl lin in ini ic ical al c cha ha h ra ra act ct ter eristi ti tics cs, as as as w we el ll as as as p p proc oc oced ed du ur ral l inf nf nfor or orma ma mati tio on on o o on n t t the e e nu nu umb mb mber er r o o of f f st t ten en nts ts, , characteristic cs s s of of o e e eac ac ach h h st st s en n nt, t, t, a a and d d l l loc oc cat a a io io on n n of of of s s st t ten en e t t t pl pl p ac ac a em em men en ent. t. t. F F Fol ol ollo lowi wi wing ng ng r r res es esea ea e rc rc rch h h et et ethi hi hics c approval l l prescribed under Ontario's health information privacy legislation, the need for informed consent was waived.
Cohort
We identified all Ontario residents who were aged 40 years or older, underwent any one of 16 excluded. In addition, we excluded low-risk ambulatory surgeries, largely because they are associated with a very low risk of major complications. 23 Furthermore, many such procedures can be performed while patients receive dual antiplatelet therapy, or delayed until dual therapy was no longer necessary.
Individuals in the cohort were categorized based on the type of stent implanted (baremetal stent or drug-eluting stent) and duration between PCI and the index surgery. These categorizations were largely informed by practice guideline recommendations that elective noncardiac surgery be delayed until at least 45 days after bare-metal-stent implantation, and 365 days after drug-eluting-stent implantation. 8 For individuals who underwent multiple PCI procedures before their index surgery, the categorization was based on the PCI closest to the esophagectomy, total abdominal hysterectomy, radical prostatectomy, nephrecto omy my my, an an nd d d cystectomy. 8, 21, 22 Information pertaining to the procedure performed and procedure status e ele le ect ct ctiv iv ive e ve ve vers rsu us n n no on on-elective) in this database is s v v ver r ry accurate. 18 I Ind n n iv vid id idu u uals who underwent C CA CAB B BG surgery ry b b bet t twe ween en t the he he p p pr re reop op per er erat ati iv ive e PC C CI and d d s su ubs s seq eq eque ue ent nt t i in nd de ex n no o on--ca card rd rdi ia iac c su su surg rg rger er ry w we wer re re ex xcl cl clud ud uded ed e . . In In In a add ddi iti io ion, n, , w w we e ex excl cl c ud ud uded ed ed l l low ow w-r -r ris is isk k k am am mbu bu ula at ato or ry y y su su surg rger er erie ie es, s, l l lar ar a g g gely ly ly b b bec ec e au au a se se se t t the hey y y a ar are e associated w wit it th h h a a ve ve very ry ry l low ow ow r r ris is isk of of of m m maj a or or or c c com om ompl pl plic ic i at at atio io ions n . . 23 
Outcomes and Comorbidities
Patients were tracked for one year after surgery for mortality, hospital readmission for an acute coronary syndrome (myocardial infarction or unstable angina), and repeat coronary revascularization (PCI or CABG surgery). The DAD (in-hospital mortality, revascularization, hospital readmission for acute coronary syndrome), Registered Persons Database (out-of-hospital mortality) and Cardiac Care Network registry (revascularization) were used to ascertain these outcomes. We identified hospitalizations for acute coronary syndromes using International Classification of Diseases 10 th Revision diagnostic codes I21, I22, I20, I23.82 and I24. 24 The primary outcome was a major adverse cardiac event (MACE) -defined as mortality, readmission for acute coronary syndrome, or coronary revascularization -within 30 days after the index surgery. The secondary outcome was MACE within one year after surgery.
Demographic information was obtained from the Registered Persons Database, while validated algorithms were used to identify diabetes and hypertension. 17, 19 The Ontario Health
Insurance Plan database was used to identify anyone who required dialysis before surgery. Using the DAD, we used previously described methods to identify other comorbidities based on
Patients were tracked for one year after surgery for mortality, hospital readmissio io on fo fo f r r r an n an a a acu cu cute te coronary syndrome (myocardial infarction or unstable angina), a r nd repeat coronary e eva va asc sc cul ul ular ar riz iz izat at a ion n n ( (P (PCI or CABG surgery). The D D DAD AD (in-hospital l mo m m rt rt tal al ali it ity, revascularization, h ho hosp p spital readm mis i issi s on on f f for or r a acu c cute te te c cor or ron on onar ary y syn nd dr rome e e), Re e eg gi gist ste e ered ed e P P Pe er rso son ns s D D Dat at tab ab abas ase e (o (o out ut u --of-f-f-ho ho hosp sp pita mo mo ort rt r al al alit it i y) y) y) a a and nd nd C Car ar rdi diac ac c C C Car are Ne Ne Netw tw twor or ork k r re regi gi gist st stry ry r ( ( (re re r va va vasc s u ul ular ar ariz iz izat atio io ion) n) ) we we were re e u use sed d d to to o a asc sc cer er erta ai i in t the hes s se outcomes. We We e i ide de dent nt ntif if i ie ie i d d d ho ho osp sp spit tal al aliz iz i at at atio ions ns n f f for or or a a acu cu c te te t c cor or o on on nar ar ary y y sy sy synd nd ndro o ome me mes s s us us usin in ing g In In Inte te tern rn rnat at a ional International Classification of Diseases (9 th or 10 th Revision) codes from hospitalizations within three years preceding surgery: congestive heart failure, cerebrovascular disease, peripheral vascular disease, pulmonary disease, and chronic renal insufficiency. 25 We determined patients' socioeconomic status based on their neighborhood median income in the Canadian census, and their residence (rural versus urban) using Statistics Canada definitions. 26 Perioperative cardiac risk was also estimated based on the Revised Cardiac Risk Index (RCRI). 27 This predictive index consists of six equally weighted components: coronary artery disease, congestive heart failure, cerebrovascular disease, diabetes, renal insufficiency, and highrisk surgery (major vascular, intra-peritoneal, or intra-thoracic procedures). It is suggested that a RCRI score of zero points corresponds to low risk, one to two points corresponds to intermediate risk, and three or more points corresponds to high risk. 28 As an additional comparison, we used the same databases to describe the characteristics and outcomes of individuals who were aged 40 years or greater, underwent eligible surgeries during the study period, and had not undergone any revascularization (PCI or CABG surgery) within 10 years before their index surgery.
To describe the preoperative use of antiplatelet medications, the Ontario Drug Benefits database was used to ascertain preoperative prescriptions for thienopyridines (clopidogrel or ticlopidine) in the 100 days before the index surgery. Since these data are only available for individuals aged 65 years or older, and a 100-day look-back period was used, this analysis was performed in the subgroup aged 66 years or older.
Analyses
We used appropriate tests (analysis of variance, Kruskal-Wallis test, chi-square test) to compare the characteristics of patients who had or had not received a bare-metal stent or drug-eluting RCRI score of zero points corresponds to low risk, one to two points correspond ds s s to to o int nt nter r erme me medi d diate isk, and three or more points corresponds to high risk. 28 As As As a a an n ad ddi di dit ti tio onal comparison, we used the he he sa ame databases s t to de de esc sc scri r be the characteristics an nd d d ou o tcomes s o of f f in n ndi di iv vi v du du dual al als s wh wh w o o we we were re e a a aged d d 4 40 ye ea ear rs o o or r gr gre ea eate ter, r, u und nder erwe we w nt nt e el li ligi gibl bl ble e su surg rg r e er erie e ies s du duri ri ring ng ng t the he s s stu tu tudy dy y pe er erio io od, d, a and nd h h had ad ad no no not t u und nd nder er erg go gone ne ne a any ny ny re ev evas as asc cu cula a ari ri r z za zati ti i t t on on on ( ( (PC C CI I o or or C C CAB AB ABG G G s s sur rg rger er ry) y) within 10 ye ear ar rs s be be efo fo fore re e t t the h ir ir ir i i ind nd n ex ex ex s sur ur u ge ge gery ry ry. stent within two years before their index surgeries. Descriptive statistics were used to characterize event rates of the primary and secondary outcomes among individuals who had undergone prior PCI (categorized based on stent type and PCI-to-surgery interval), and among non-revascularized individuals (categorized based on RCRI score). 27 We then used multivariable logistic regression to determine the adjusted association between the nine categories of stent type and PCI-to-surgery interval with the primary and secondary outcomes. The reference category, against which the different categories of the primary exposure were compared, was a history of remote stenting (i.e. bare-metal or drugeluting stent within 731 days to 10 years before surgery). The other covariates in the regression model were age, sex, surgery, congestive heart failure, cerebrovascular disease, peripheral vascular disease, hypertension, diabetes, and renal disease. Surgeries were categorized as major vascular (abdominal aortic aneurysm repair, peripheral vascular bypass), high-intermediate-risk
(large bowel resection, partial liver resection, Whipple procedure, pneumonectomy, pulmonary lobectomy, gastrectomy, esophagectomy cystectomy, nephrectomy), and low-intermediate-risk
(carotid endarterectomy, total hip replacement, total knee replacement, total abdominal hysterectomy, radical prostatectomy) procedures. 29 Model discrimination was measured using the c-statistic, while calibration was estimated using the Hosmer-Lemeshow statistic.
All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC) and a twotailed P-value less than 0.05 was used to define statistical significance.
Results
The cohort consisted of 8116 patients who underwent stent implantation within 10 years before their non-cardiac surgery. Approximately 34% (n=2725) underwent stent implantation within model were age, sex, surgery, congestive heart failure, cerebrovascular disease, pe p peri ri iph ph her er eral al al vascular disease, hypertension, diabetes, and renal disease. Surgeries were categorized as major va asc sc cul ul ula ar ar ( ( (ab ab abdo d d mi mi min na nal l aortic aneurysm repair, peri ri iph ph p e eral vascular by by bypa ass ss s) ), ), high-intermediate-risk l l lar rg ge g bowel r res ese ec ect tion on n, p pa part rt rtia ia al l li live ve er r re re r s se sec ction n n, Wh hip p pple e e p p pro roc ce cedu dur re, pn pneu eu um mo mon ne nec ct ctom om my, y, p pu ul u m mo mon na nar ry ry o obe be bect ct ctom om o y, y, y, g g gas astr tr rec c cto tomy my my, , , es e op op pha ha hage ge gect ct ctom om my y y cy cy cyst stec ec ecto to om m my, y, y n nep ep eph hr hrec ec cto to t my my my), ), ), a a and nd nd l low ow w-i -i -int nte er erm m med d dia at ate-e-r r risk sk k m m m carotid endar ar rte te tere re r ct ct ctom om omy, y, y tot ot otal al al h h hip ip ip r rep ep epla a ace ce ceme me men n nt, t, t t tot ot o al al al k kne ne ee e e re re repl pl plac ac acem em emen en ent, t, t t t tot ot otal al al a abd bd bdom om omin in nal a two years before surgery; of these individuals, 905 (33%) received drug-eluting stents. The proportion that had received drug-eluting stents within two years before surgery varied over the study period (Online Data Supplement, Supplemental Figure 1 ). Compared to individuals with remote histories of stent implantation (i.e. 731 days to 10 years before non-cardiac surgery), patients who received bare-metal or drug-eluting stents within two years before surgery differed with regard to surgical procedure and comorbidities ( Table 1) .
The separate comparator group of patients, who were aged 40 years or greater, underwent eligible surgeries, and had not undergone coronary revascularization within 10 years before their index surgery, consisted of 341,350 individuals. Their characteristics are presented in the Online Data Supplement (Supplemental Table 1 ).
Among individuals who had undergone prior PCI, the overall risk of 30-day MACE was relatively low at 2.1% (n=170), while the risk of 1-year MACE was 9.8% (n=798). The rate of postoperative mortality was 1.2% (n=100) at 30-days and 5.2% (n=419) at one-year. The Data Supplement (Supplemental Table 1 ).
Among individuals who had undergone prior PCI, the overall risk of 30-day MACE was e ela la ati ti tive ve vel ly ly l l low ow ow at t 2 2. 2.1% 1 (n=170), while the risk of f f 1 1--y year MACE w w was a a 9 9.8 . Table 2 ).
Discussion
In this population-based study, we found that the risk of perioperative MACE was highest when major elective non-cardiac surgery was performed less than 45 days after coronary stent implantation. The earliest optimal time for performing surgery appeared to be from 46 to 180 days after bare-metal-stent implantation, or more than 180 days after drug-eluting-stent implantation. Thus, these findings help inform clinical decision-making regarding the timing of major elective non-cardiac surgery following recent PCI.
Implications ndividuals who received a bare-metal stent within two years before surgery, 68.9 .9 9% % % (n n n=4 =4 =404 04 04) ) ) among the 586 individuals who received a drug-eluting stent within two years before surgery, Our findings suggest that elective non-cardiac surgery can be performed reasonably safely in carefully selected patients once at least six months had elapsed since drug-eluting-stent implantation. There may also be an "optimal" time window for performing surgery within the year following bare-metal-stent implantation, namely from 46 to 180 days after PCI. While the presence of this "optimal" window is not certain, especially because its associated adjusted odds ratio is imprecise, this window is biologically plausible. It represents the period when reendothelialization is largely complete after bare-metal-stent implantation, 30 but when in-stent
restenosis has yet to completely manifest itself. 31 Conversely, once more than one year has elapsed since either bare-metal or drug-eluting stent implantation, physicians can reassured that the associated perioperative cardiac risk has reached a plateau, with risks similar to that of individuals with remote histories of previous PCI (i.e. two to 10 years before surgery).
Importantly, our results also indicate that the absolute magnitude of short-term postoperative risk is not unreasonable during these periods, namely 45 to 180 days after baremetal stent implantation and more than 180 days after drug-eluting-stent implantation.
Specifically, perioperative risks during these intervals approach that of an intermediate risk nonrevascularized patient with one to two risk factors. This absolute risk is important for clinicians to consider when weighing the risks of proceeding with elective surgery following PCI against the risks of not operating in individuals who require surgery for conditions such as cancer.
Our study has implications for current guideline recommendations pertaining to the perioperative care of patients with coronary stents. While our results do support the recommendation to delay elective non-cardiac surgery until at least 30 to 45 days have elapsed since bare-metal-stent implantation, they further suggest that excessive delays are not helpful.
Specifically, short-term perioperative cardiac risk might rise once more than 180 days have he associated perioperative cardiac risk has reached a plateau, with risks similar r to to t tha ha at t t of of of ndividuals with remote histories of previous PCI (i.e. two to 10 years before surgery).
Im Im Impo po p r r rtan n ntl tl tly y, y, our results also indicate tha at t t th the e absolute mag ag gnitu ude de de of short-term post st top o erative ri ri isk sk s is s no n not t un un nre re eas a ason ona a ab bl ble e du du urin ng g t thes se p per r rio io ods ds, , , n na nam m mel ly y 4 45 5 5 to o o 1 180 80 80 d day ay ys s af af afte te er ba b bare re eme me eta ta tal l l st st s en ent t t im im impl plan an anta tati tion on n a and nd m m mor or ore e e th th than an n 1 1 180 80 80 da a ays ys y a af ft fter er r d dru ru rug g-g-el el lut ut u i in ing-g-g-st st s e en ent t im im mpl pl p an an a ta ta ati ti io on on. .
Specifically y, , , pe pe peri ri r op op oper er e at at a iv iv i e e ri ri r sk sk s s s s du du d ri ri ring ng g t t the he hese se se i i int nt n er er e va va vals ls l a a app pp ppro ro roac ac ach h h th t t at at at o o of f f an an an i i int nt n er er erme me medi di d at at a e risk non---elapsed since PCI. Conversely, whereas guidelines recommend that surgery be delayed until one year after drug-eluting-stent implantation, 8 our findings instead suggest that surgery can be performed reasonably safely following a six-month delay.
Our results have both important similarities and differences with respect to previous investigations of non-cardiac surgery following coronary stent implantation. We confirmed observations of substantially increased risk when surgery is performed within six weeks of coronary stent implantation. 4, 10, 12, 13 In addition, our study is largely consistent with previous research showing that cardiac risk is relatively low if elective surgery is delayed by six months or more after drug-eluting-stent implantation. [32] [33] [34] Our findings also corroborate a prior study where discontinuation of dual antiplatelet therapy after six months was not associated with increased rates of stent thrombosis following drug-eluting-stent implantation. 35 Conversely, our findings differ from some prior studies with respect to rates of perioperative MACE. infarction and repeat revascularization were considered, the event rate was 22% instead. 4 Similarly, while Godet et al. reported a 12% rate of elevated troponin concentrations, the rate of myocardial infarction or death was 4%. 36 discontinuation of dual antiplatelet therapy after six months was not associated w w wit ith h h in n ncr cr crea ea ease se sed d
ates of stent thrombosis following drug-eluting-stent implantation. 35 Co Co Conv nv n e e erse e ely ly ly, , our findings differ from som m me e e p p prior studies wi wi ith t r res es sp pe pect to rates of In a previous study that used administrative databases, Cruden et al. reported a 14% rate of postoperative death or ischemic events. Notably, the adverse event rate remained elevated at 11% rate even when surgery was performed more than one year after PCI. 10 These differences may be explained the investigators' use of administrative data to identify postoperative inhospital cardiac complications. Previous research has shown that administrative data generally do not accurately capture in-hospital complications. 37 In contrast, the components of our primary outcome -mortality, readmission for acute coronary syndrome, or revascularization -are accurately captured by administrative databases. 18, 24 Notably, rates of postoperative death, which are generally accurately captured by administrative data, in the study by Cruden et al. were considerably lower at only 0.6%.
The major strength of our study is the generalizability associated with its populationbased sample. Additionally, the cohort only included elective procedures, thereby focusing the analysis on the clinically relevant situation where physicians must decide whether to delay elective surgery to minimize perioperative risk related to coronary stents. Conversely, for nonelective procedures, surgery usually proceeds regardless of the interval since recent PCI, and the main issue is how best to manage patients' antiplatelet medications.
Our study also has several limitations. First, despite being one of the largest evaluations of non-cardiac surgery following stent implantation, event rates were relatively low, thereby limiting our statistical power. Many estimates from multivariable analyses therefore had wide confidence intervals, and smaller subgroups within patients who underwent prior PCI (e.g. strata defined by RCRI score) could not be evaluated. Second, administrative databases generally do not accurately capture in-hospital complications. 37 We could not therefore ascertain several postoperative complications that are directly relevant to this study, such as non-fatal myocardial considerably lower at only 0.6%.
The major strength of our study is the generalizability associated with its populationd ba ase se ed d d s sa samp mp mpl le le. Ad Ad dd di diti t onally, the cohort only inclu lu lude de ed elective proc oc cedur ur res es es, , thereby focusing the an nal al lys y is on th he e cl c c in n nic ca al a ly y y r r re el elev ev evan ant t si si itu tua a ati ion wh wh where e p ph hys s sic ic cia ian n ns m mu u ust t d dec ecid id i e e wh wh whe et ethe her r r to to o d d del la ay ay el lec ec ecti ti ive ve ve s sur ur rge ge g ry ry t to o mi mini nim mi mize ze p p per er rio io iope p pera ra ati tive ve ve r r ri isk k k re rela late te t d d d to to o c c co o oron on onar ar ary y st st sten en nts s. . Co Co Conv nv nver er rse se sely ly, , fo o or r no no on-n--elective proce ce edu du dure re es, s, s, s sur ur urge g g ry ry ry u u usu u ual al ally ly y p pro ro roce ce eed ed ds s s re re rega ga gard rd rdle less ss s o o of f f th th the e e in in inte e erv rv rval al a s s si i inc nc nce e re re rece ce cent nt nt P P PCI, and the e e infarction, stent thrombosis, and clinically significant bleeding. Nonetheless, the primary outcome includes all significant sequelae of a postoperative myocardial infarction, namely death, repeat revascularization or hospital re-admission for acute coronary syndrome. Third, our databases did not capture in-hospital medications or outpatient aspirin use; furthermore, they did not describe whether patients had briefly discontinued their aspirin or thienopyridine use before surgery. Indeed, the absence of information on in-hospital medications may explain the paradoxically lower rate of thienopyridine use among patients who had non-cardiac surgery less than 45 days after stent insertion (Online Data Supplement, Supplemental Table 1 ). Fourth, the PCI registry lacked some detailed procedural information (e.g. bifurcational stenting, poor runoff) that may have influenced both patients' perioperative risks and clinicians' willingness to discontinue anti-platelet therapy earlier than recommended by practice guidelines.
Fifth, survivor bias and unmeasured confounding may explain, in part, the lower event rates among individuals with longer delays between PCI and non-cardiac surgery. For example, when compared to anyone who underwent surgery shortly after PCI, such patients would have to survive longer after PCI without dying or needing repeat revascularization. Thus, any individual with unstable coronary artery disease requiring repeat revascularization would either be excluded if CABG was performed, or reclassified as having a shorter interval from PCI to surgery. In addition, the performance of elective surgery sooner after PCI may have been a marker of more urgent procedures that were themselves associated with increased perioperative risk. Sixth, changing practice guidelines might explain, in part, the reduced risk of MACE when surgery was performed more than six months following drug-eluting stent insertion. Specifically, prior to the updating of perioperative practice guidelines in 2007, 7 PCI-specific guidelines recommended clopidogrel therapy for only three months after sirolimus stent implantation, and six months after off) that may have influenced both patients' perioperative risks and clinicians' wi wi ill lin in i gn gn gnes s ess s s to to to discontinue anti-platelet therapy earlier than recommended by practice guidelines.
Fi Fi Fift ft fth h h, su urv rv rvi iv ivor bias and unmeasured con nfo fo fou un nding may exp p pla l in n, , in in in part, the lower event a ate e es s among in ndi di divi i idu ua al a s s i wi with th th l l lon onge ge ger r r d de ela ays b b be e etwe een n n PCI CI CI a an nd nd n non on n--ca card rd dia i c c c su su urg rg ger ery. y. y. F F For or ex xa xam mp mpl l le, wh wh hen en en c c com ompa pa pare red d to to a any ny nyon on ne e wh wh who o un un unde de derw rw wen en ent t t s s surg rg rger er ry y s sho o ort rt tly ly ly a aft ft ter er e P P PCI CI CI, , su su uc ch h pa pa ati ti ien en e ts ts s w w wou u uld d d h hav a ave e e to t urvive long g ger er r a a aft fter er er P PCI CI CI wi wi with th thou ou out t t dy dy dyin in ing g g or or or n n nee ee eedi di ding ng ng r r rep ep epea a at t t re re reva va v sc sc scul u u ar ar riz iz izat at atio io ion. n. n. T Thu hu hus, s, s, a a any ny ny individual l paclitaxel stent implantation. 38 Performance of surgery more than six months after drug-eluting stent implantation may therefore be a marker of more compliant physicians whose patients generally had better overall outcomes.
Conclusions
In this population-based study, the earliest optimal time for performing elective non-cardiac surgery appeared to be from 46 to 180 days after bare-metal-stent implantation, or more than 180 days after drug-eluting-stent implantation. In addition to being relevant to future practice guidelines, these findings will help inform clinical decision-making when weighing the risks of operative versus non-operative therapy in patients being considered for major elective noncardiac surgery following recent coronary stent implantation. 
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